0001236215-21-000010.txt : 20210517
0001236215-21-000010.hdr.sgml : 20210517
20210517173455
ACCESSION NUMBER: 0001236215-21-000010
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210514
FILED AS OF DATE: 20210517
DATE AS OF CHANGE: 20210517
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Watson Robert Eugene
CENTRAL INDEX KEY: 0001511858
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-11889
FILM NUMBER: 21932744
MAIL ADDRESS:
STREET 1: 245 N. HIGHLAND AVE NE
STREET 2: SUITE 230-296
CITY: ATLANTA
STATE: GA
ZIP: 30307
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CEL SCI CORP
CENTRAL INDEX KEY: 0000725363
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 840916344
STATE OF INCORPORATION: CO
FISCAL YEAR END: 0930
BUSINESS ADDRESS:
STREET 1: 8229 BOONE BLVD .
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
BUSINESS PHONE: 7035069460
MAIL ADDRESS:
STREET 1: 8229 BOONE BLVD.
STREET 2: SUITE 802
CITY: VIENNA
STATE: VA
ZIP: 22182
FORMER COMPANY:
FORMER CONFORMED NAME: INTERLEUKIN 2 INC
DATE OF NAME CHANGE: 19880317
4
1
primary_doc.xml
PRIMARY DOCUMENT
X0306
4
2021-05-14
0
0000725363
CEL SCI CORP
CVM
0001511858
Watson Robert Eugene
245 N. HIGHLAND AVE NE
SUITE 230-296
ATLANTA
GA
30307
1
0
0
0
Options
20.61
2021-05-14
4
A
0
128000
0.01
A
2031-05-13
Common Stock
128000
506000
D
Each option entitles the holder to purchase one share of the Company's common stock at a price of $20.61 per share. The stock options vest 100% upon either (a) the filing of the first marketing application for any pharmaceutical based upon the Company's Multikine technology in any of the USA, Canada, UK, Germany, France, Italy, Spain, Japan, or Australia, or (b) if the closing price of the Company's common stock exceeds $42.00 for one trading day. None of the options will be exercisable before May 13, 2022.
Robert Watson
2021-05-17